- Home
- ROIV vs PAYC Comparison
ROIV vs PAYC Comparison
Compare ROIV & PAYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- PAYC
- Stock Information
- Founded
- ROIV 2014
- PAYC 1998
- Country
- ROIV United Kingdom
- PAYC United States
- Employees
- ROIV N/A
- PAYC N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- PAYC Computer Software: Prepackaged Software
- Sector
- ROIV Health Care
- PAYC Technology
- Exchange
- ROIV Nasdaq
- PAYC Nasdaq
- Market Cap
- ROIV 8.4B
- PAYC 9.6B
- IPO Year
- ROIV N/A
- PAYC 2014
- Fundamental
- Price
- ROIV $11.83
- PAYC $227.07
- Analyst Decision
- ROIV Strong Buy
- PAYC Hold
- Analyst Count
- ROIV 9
- PAYC 11
- Target Price
- ROIV $17.69
- PAYC $193.67
- AVG Volume (30 Days)
- ROIV 4.5M
- PAYC 740.5K
- Earning Date
- ROIV 11-12-2024
- PAYC 10-30-2024
- Dividend Yield
- ROIV N/A
- PAYC 0.66%
- EPS Growth
- ROIV N/A
- PAYC 42.02
- EPS
- ROIV 5.89
- PAYC 8.29
- Revenue
- ROIV $129,128,999.00
- PAYC $1,823,922,000.00
- Revenue This Year
- ROIV $48.37
- PAYC $12.65
- Revenue Next Year
- ROIV $13.76
- PAYC $10.53
- P/E Ratio
- ROIV $2.01
- PAYC $27.38
- Revenue Growth
- ROIV 145.68
- PAYC 11.92
- 52 Week Low
- ROIV $8.61
- PAYC $139.50
- 52 Week High
- ROIV $13.06
- PAYC $233.69
- Technical
- Relative Strength Index (RSI)
- ROIV 51.97
- PAYC 72.76
- Support Level
- ROIV $11.05
- PAYC $213.07
- Resistance Level
- ROIV $12.05
- PAYC $231.10
- Average True Range (ATR)
- ROIV 0.30
- PAYC 5.63
- MACD
- ROIV -0.02
- PAYC -1.01
- Stochastic Oscillator
- ROIV 61.86
- PAYC 73.33
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About PAYC Paycom Software Inc.
Paycom is a fast-growing provider of payroll and human capital management software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 19,500 clients as of 2023, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.